LIVIVO - Search results -

Search results

Result 1 - 10 of total 115

Book: Endocannabinoids

Pertwee, R. G

(Handbook of experimental pharmacology ; v.231)

2015

Author's details	Roger G. Pertwee, editor
Series title	Handbook of experimental pharmacology ; v.231
MeSH term(s)	Endocannabinoids/physiology ; Cannabinoid Receptor Modulators/pharmacology ; Endocannabinoids/pharmacology ; Receptors, Cannabinoid/therapeutic use
Language	English
Size	xii, 475 p. :, ill. (chiefly col.) ;, 24 cm.
Publisher	Springer
Publishing place	Cham ; New York
Document type	Book
ISBN	9783319208244 ; 3319208241
Database	Catalogue of the US National Library of Medicine (NLM)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Book: Handbook of cannabis

Pertwee, R. G

(Handbooks in psychopharmacology)

2014

Author's details	edited by Roger G. Pertwee
Series title	Handbooks in psychopharmacology
MeSH term(s)	Cannabis ; Medical Marijuana ; Cannabinoids ; Phytotherapy
Language	English
Size	xxiv, 747 pages, 8 unnumbered pages of plates :, illustrations ;, 25 cm
Document type	Book
ISBN	9780199662685 ; 0199662681
Database	Catalogue of the US National Library of Medicine (NLM)

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists.

Pertwee, R G

Current medicinal chemistry

2010 Volume 17, Issue 14, Page(s) 1360–1381

Abstract: It is widely accepted that non-endogenous compounds that target CB(1) and/or CB(2) receptors possess therapeutic potential for the clinical management of an ever growing number of disorders. Just a few of these disorders are already treated with Delta(9)- ...

Abstract	It is widely accepted that non-endogenous compounds that target CB(1) and/or CB(2) receptors possess therapeutic potential for the clinical management of an ever growing number of disorders. Just a few of these disorders are already treated with Delta(9)-tetrahydrocannabinol or nabilone, both CB(1)/CB(2) receptor agonists, and there is now considerable interest in expanding the clinical applications of such agonists and also in exploiting CB(2)-selective agonists, peripherally restricted CB(1)/CB(2) receptor agonists and CB(1)/CB(2) antagonists and inverse agonists as medicines. Already, numerous cannabinoid receptor ligands have been developed and their interactions with CB(1) and CB(2) receptors well characterized. This review describes what is currently known about the ability of such compounds to bind to, activate, inhibit or block non-CB(1), non- CB(2) G protein-coupled receptors such as GPR55, transmitter gated channels, ion channels and nuclear receptors in an orthosteric or allosteric manner. It begins with a brief description of how each of these ligands interacts with CB(1) and/or CB(2) receptors.
MeSH term(s)	Cannabinoid Receptor Agonists ; Cannabinoid Receptor Antagonists ; Dronabinol/analogs & derivatives ; Dronabinol/pharmacology ; Ion Channels/metabolism ; Ligands ; Piperidines/chemistry ; Piperidines/pharmacology ; Pyrazoles/chemistry ; Pyrazoles/pharmacology ; Receptors, Cannabinoid/metabolism ; Receptors, Cytoplasmic and Nuclear/metabolism ; Receptors, G-Protein-Coupled/metabolism ; Rimonabant
Chemical Substances	Cannabinoid Receptor Agonists ; Cannabinoid Receptor Antagonists ; Ion Channels ; Ligands ; Piperidines ; Pyrazoles ; Receptors, Cannabinoid ; Receptors, Cytoplasmic and Nuclear ; Receptors, G-Protein-Coupled ; Dronabinol (7J8897W37S) ; Rimonabant (RML78EN3XE)
Language	English
Publishing date	2010-02-17
Publishing country	United Arab Emirates
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	1319315-6
ISSN	1875-533X ; 0929-8673
ISSN (online)	1875-533X
ISSN	0929-8673
DOI	10.2174/092986710790980050
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4432: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

Pertwee, R G

British journal of pharmacology

2008 Volume 153, Issue 2, Page(s) 199–215

Abstract: Cannabis sativa is the source of a unique set of compounds known collectively as plant cannabinoids or phytocannabinoids. This review focuses on the manner with which three of these compounds, (-)-trans-delta9-tetrahydrocannabinol (delta9-THC), (-)- ... ...

Abstract	Cannabis sativa is the source of a unique set of compounds known collectively as plant cannabinoids or phytocannabinoids. This review focuses on the manner with which three of these compounds, (-)-trans-delta9-tetrahydrocannabinol (delta9-THC), (-)-cannabidiol (CBD) and (-)-trans-delta9-tetrahydrocannabivarin (delta9-THCV), interact with cannabinoid CB1 and CB2 receptors. Delta9-THC, the main psychotropic constituent of cannabis, is a CB1 and CB2 receptor partial agonist and in line with classical pharmacology, the responses it elicits appear to be strongly influenced both by the expression level and signalling efficiency of cannabinoid receptors and by ongoing endogenous cannabinoid release. CBD displays unexpectedly high potency as an antagonist of CB1/CB2 receptor agonists in CB1- and CB2-expressing cells or tissues, the manner with which it interacts with CB2 receptors providing a possible explanation for its ability to inhibit evoked immune cell migration. Delta9-THCV behaves as a potent CB2 receptor partial agonist in vitro. In contrast, it antagonizes cannabinoid receptor agonists in CB1-expressing tissues. This it does with relatively high potency and in a manner that is both tissue and ligand dependent. Delta9-THCV also interacts with CB1 receptors when administered in vivo, behaving either as a CB1 antagonist or, at higher doses, as a CB1 receptor agonist. Brief mention is also made in this review, first of the production by delta9-THC of pharmacodynamic tolerance, second of current knowledge about the extent to which delta9-THC, CBD and delta9-THCV interact with pharmacological targets other than CB1 or CB2 receptors, and third of actual and potential therapeutic applications for each of these cannabinoids.
MeSH term(s)	Animals ; Cannabidiol/pharmacology ; Dronabinol/analogs & derivatives ; Dronabinol/pharmacology ; Drug Tolerance ; Humans ; Receptor, Cannabinoid, CB1/agonists ; Receptor, Cannabinoid, CB1/antagonists & inhibitors ; Receptor, Cannabinoid, CB1/drug effects ; Receptor, Cannabinoid, CB2/agonists ; Receptor, Cannabinoid, CB2/antagonists & inhibitors ; Receptor, Cannabinoid, CB2/drug effects ; Synaptic Transmission/drug effects
Chemical Substances	Receptor, Cannabinoid, CB1 ; Receptor, Cannabinoid, CB2 ; Cannabidiol (19GBJ60SN5) ; tetrahydrocannabivarin 9 (28172-17-0) ; Dronabinol (7J8897W37S)
Language	English
Publishing date	2008-01
Publishing country	England
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	80081-8
ISSN	1476-5381 ; 0007-1188
ISSN (online)	1476-5381
ISSN	0007-1188
DOI	10.1038/sj.bjp.0707442
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uf I Zs.146: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: GPR55: a new member of the cannabinoid receptor clan?

Pertwee, R G

British journal of pharmacology

2007 Volume 152, Issue 7, Page(s) 984–986

Abstract: In this issue of the British Journal of Pharmacology, Ryberg et al. present convincing in vitro evidence that the orphan GPCR, GPR55, is a cannabinoid receptor. GPR55 was activated by a range of plant, synthetic and endogenous cannabinoids and blocked by ...

Abstract	In this issue of the British Journal of Pharmacology, Ryberg et al. present convincing in vitro evidence that the orphan GPCR, GPR55, is a cannabinoid receptor. GPR55 was activated by a range of plant, synthetic and endogenous cannabinoids and blocked by the non-psychoactive phytocannabinoid, cannabidiol. Their experiments have revealed several differences between the pharmacology of GPR55 and the established cannabinoid CB1 and CB2 receptors. For example, the CB1 receptor antagonist, AM251, activated GPR55 and the main psychoactive constituent of cannabis, Delta9-tetrahydrocannabinol, displayed greater efficacy at GPR55 than at CB1 or CB2 receptors. They also compared the distribution of GPR55 and CB1 mRNA in mouse and report that GPR55 couples to Galpha13, that it is activated by virodhamine, palmitoylethanolamide and oleoylethanolamide, and that virodhamine displays relatively high efficacy as a GPR55 agonist. Still to be identified are the main roles played by GPR55 in health and disease and any potential therapeutic benefits of activating or blocking this receptor.
MeSH term(s)	Animals ; Arachidonic Acids/pharmacology ; Cannabinoids ; Dronabinol/pharmacology ; Endocannabinoids ; Ethanolamines ; Humans ; Oleic Acids/pharmacology ; Palmitic Acids/pharmacology ; Piperidines/pharmacology ; Pyrazoles/pharmacology ; Receptors, G-Protein-Coupled/agonists ; Receptors, G-Protein-Coupled/drug effects ; Receptors, G-Protein-Coupled/physiology
Chemical Substances	Arachidonic Acids ; Cannabinoids ; Endocannabinoids ; Ethanolamines ; GPR55 protein, human ; Oleic Acids ; Palmitic Acids ; Piperidines ; Pyrazoles ; Receptors, G-Protein-Coupled ; virodhamine ; oleoylethanolamide (1HI5J9N8E6) ; AM 251 (3I4FA44MAI) ; palmidrol (6R8T1UDM3V) ; Dronabinol (7J8897W37S)
Language	English
Publishing date	2007-09-17
Publishing country	England
Document type	Journal Article ; Review ; Comment
ZDB-ID	80081-8
ISSN	1476-5381 ; 0007-1188
ISSN (online)	1476-5381
ISSN	0007-1188
DOI	10.1038/sj.bjp.0707464
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uf I Zs.146: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: The pharmacology of cannabinoid receptors and their ligands: an overview.

Pertwee, R G

International journal of obesity (2005)

2006 Volume 30 Suppl 1, Page(s) S13–8

Abstract: Mammalian tissues express at least two cannabinoid receptor types, CB1 and CB2, both G protein coupled. CB1 receptors are found predominantly at nerve terminals where they mediate inhibition of transmitter release. CB2 receptors occur mainly on immune ... ...

Abstract	Mammalian tissues express at least two cannabinoid receptor types, CB1 and CB2, both G protein coupled. CB1 receptors are found predominantly at nerve terminals where they mediate inhibition of transmitter release. CB2 receptors occur mainly on immune cells, one of their roles being to modulate cytokine release. Endogenous agonists for cannabinoid receptors also exist, and are all eicosanoids. The first-discovered of these 'endocannabinoids' was arachidonoylethanolamide and there is convincing evidence that this ligand and some of its metabolites can activate vanilloid VRI (TRPV1) receptors. Certain cannabinoids also appear to have TRPV1-like and/or non-CB1, non-CB2, non-TRPV1 targets. Several CB1- and CB2-selective agonists and antagonists have been developed. Antagonists include the CB1-selective SR141716A, AM251, AM281 and LY320135, and the CB2-selective SR144528 and AM630. These all behave as inverse agonists, one indication that CB1 and CB2 receptors can exist in a constitutively active state. 'Neutral' cannabinoid receptor antagonists have also been developed. CB1 and/or CB2 receptor activation appears to ameliorate inflammatory and neuropathic pain and certain multiple sclerosis symptoms. This might be exploited clinically by using CB1, CB2 or CB1/CB2 agonists, or inhibitors of the membrane transport or catabolism of endocannabinoids that are released in increased amounts, at least in animal models of pain and multiple sclerosis. We have recently discovered the presence of an allosteric site on the CB1 receptor. Consequently, it may also prove possible to enhance 'autoprotective' effects of released endocannabinoids with CB1 allosteric enhancers or, indeed, to reduce proposed 'autoimpairing' effects of released endocannabinoids such as excessive food intake with CB1 allosteric antagonists.
MeSH term(s)	Animals ; Cannabinoid Receptor Agonists ; Cannabinoid Receptor Antagonists ; Cannabinoid Receptor Modulators/metabolism ; Humans ; Multiple Sclerosis/drug therapy ; Multiple Sclerosis/metabolism ; Nerve Endings/metabolism ; Pain/drug therapy ; Pain/metabolism ; Receptor, Cannabinoid, CB1/agonists ; Receptor, Cannabinoid, CB1/antagonists & inhibitors ; Receptor, Cannabinoid, CB2/agonists ; Receptor, Cannabinoid, CB2/antagonists & inhibitors ; Receptors, Cannabinoid/metabolism
Chemical Substances	Cannabinoid Receptor Agonists ; Cannabinoid Receptor Antagonists ; Cannabinoid Receptor Modulators ; Receptor, Cannabinoid, CB1 ; Receptor, Cannabinoid, CB2 ; Receptors, Cannabinoid
Language	English
Publishing date	2006-04
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	752409-2
ISSN	1476-5497 ; 0307-0565
ISSN (online)	1476-5497
ISSN	0307-0565
DOI	10.1038/sj.ijo.0803272
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1325: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Pharmacological actions of cannabinoids.

Pertwee, R G

Handbook of experimental pharmacology

2006 , Issue 168, Page(s) 1–51

Abstract: Mammalian tissues express at least two types of cannabinoid receptor, CB1 and CB2, both G protein coupled. CB1 receptors are expressed predominantly at nerve terminals where they mediate inhibition of transmitter release. CB2 receptors are found mainly ... ...

Abstract	Mammalian tissues express at least two types of cannabinoid receptor, CB1 and CB2, both G protein coupled. CB1 receptors are expressed predominantly at nerve terminals where they mediate inhibition of transmitter release. CB2 receptors are found mainly on immune cells, one of their roles being to modulate cytokine release. Endogenous ligands for these receptors (endocannabinoids) also exist. These are all eicosanoids; prominent examples include arachidonoylethanolamide (anandamide) and 2-arachidonoyl glycerol. These discoveries have led to the development of CB1- and CB2-selective agonists and antagonists and of bioassays for characterizing such ligands. Cannabinoid receptor antagonists include the CB1-selective SR141716A, AM251, AM281 and LY320135, and the CB2-selective SR144528 and AM630. These all behave as inverse agonists, one indication that CB1 and CB2 receptors can exist in a constitutively active state. Neutral cannabinoid receptor antagonists that seem to lack inverse agonist properties have recently also been developed. As well as acting on CB1 and CB2 receptors, there is convincing evidence that anandamide can activate transient receptor potential vanilloid type 1 (TRPV1) receptors. Certain cannabinoids also appear to have non-CB1, non-CB2, non-TRPV1 targets, for example CB2-like receptors that can mediate antinociception and "abnormal-cannabidiol" receptors that mediate vasorelaxation and promote microglial cell migration. There is evidence too for TRPV1-like receptors on glutamatergic neurons, for alpha2-adrenoceptor-like (imidazoline) receptors at sympathetic nerve terminals, for novel G protein-coupled receptors for R-(+)-WIN55212 and anandamide in the brain and spinal cord, for novel receptors for delta9-tetrahydrocannabinol and cannabinol on perivascular sensory nerves and for novel anandamide receptors in the gastro-intestinal tract. The presence of allosteric sites for cannabinoids on various ion channels and non-cannabinoid receptors has also been proposed. In addition, more information is beginning to emerge about the pharmacological actions of the non-psychoactive plant cannabinoid, cannabidiol. These recent advances in cannabinoid pharmacology are all discussed in this review.
MeSH term(s)	Animals ; Biological Assay ; Cannabinoids/pharmacology ; Humans ; Ligands ; Receptor, Cannabinoid, CB1/classification ; Receptor, Cannabinoid, CB1/drug effects ; Receptor, Cannabinoid, CB1/physiology ; Receptor, Cannabinoid, CB2/drug effects ; Receptor, Cannabinoid, CB2/physiology ; TRPV Cation Channels/drug effects ; TRPV Cation Channels/physiology
Chemical Substances	Cannabinoids ; Ligands ; Receptor, Cannabinoid, CB1 ; Receptor, Cannabinoid, CB2 ; TRPV Cation Channels ; TRPV1 receptor
Language	English
Publishing date	2006-03-28
Publishing country	Germany
Document type	Journal Article ; Review
ISSN	0171-2004
ISSN	0171-2004
DOI	10.1007/3-540-26573-2_1
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Sign. bis Bd. 125 (1997): 1982 A 2146: Show issues
danach: Sign. bei den Einzelbänden: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Cannabinoids and the gastrointestinal tract.

Pertwee, R G

Gut

2001 Volume 48, Issue 6, Page(s) 859–867

Abstract: The enteric nervous system of several species, including the mouse, rat, guinea pig and humans, contains cannabinoid CB1 receptors that depress gastrointestinal motility, mainly by inhibiting ongoing contractile transmitter release. Signs of this ... ...

Abstract	The enteric nervous system of several species, including the mouse, rat, guinea pig and humans, contains cannabinoid CB1 receptors that depress gastrointestinal motility, mainly by inhibiting ongoing contractile transmitter release. Signs of this depressant effect are, in the whole organism, delayed gastric emptying and inhibition of the transit of non-absorbable markers through the small intestine and, in isolated strips of ileal tissue, inhibition of evoked acetylcholine release, peristalsis, and cholinergic and non-adrenergic non-cholinergic (NANC) contractions of longitudinal or circular smooth muscle. These are contractions evoked electrically or by agents that are thought to stimulate contractile transmitter release either in tissue taken from morphine pretreated animals (naloxone) or in unpretreated tissue (gamma-aminobutyric acid and 5-hydroxytryptamine). The inhibitory effects of cannabinoid receptor agonists on gastric emptying and intestinal transit are mediated to some extent by CB1 receptors in the brain as well as by enteric CB1 receptors. Gastric acid secretion is also inhibited in response to CB1 receptor activation, although the detailed underlying mechanism has yet to be elucidated. Cannabinoid receptor agonists delay gastric emptying in humans as well as in rodents and probably also inhibit human gastric acid secretion. Cannabinoid pretreatment induces tolerance to the inhibitory effects of cannabinoid receptor agonists on gastrointestinal motility. Findings that the CB1 selective antagonist/inverse agonist SR141716A produces in vivo and in vitro signs of increased motility of rodent small intestine probably reflect the presence in the enteric nervous system of a population of CB1 receptors that are precoupled to their effector mechanisms. SR141716A has been reported not to behave in this manner in the myenteric plexus-longitudinal muscle preparation (MPLM) of human ileum unless this has first been rendered cannabinoid tolerant. Nor has it been found to induce "withdrawal" contractions in cannabinoid tolerant guinea pig ileal MPLM. Further research is required to investigate the role both of endogenous cannabinoid receptor agonists and of non-CB1 cannabinoid receptors in the gastrointestinal tract. The extent to which the effects on gastrointestinal function of cannabinoid receptor agonists or antagonists/inverse agonists can be exploited therapeutically has yet to be investigated as has the extent to which these drugs can provoke unwanted effects in the gastrointestinal tract when used for other therapeutic purposes.
MeSH term(s)	Acetylcholine/physiology ; Animals ; Cannabinoids/pharmacology ; Digestive System/drug effects ; Digestive System Physiological Phenomena ; Drug Tolerance/physiology ; Electric Stimulation ; Enteric Nervous System/drug effects ; Gastric Acid/metabolism ; Gastric Emptying/drug effects ; Gastric Emptying/physiology ; Gastrointestinal Motility/drug effects ; Gastrointestinal Motility/physiology ; Guinea Pigs ; Hallucinogens/pharmacology ; Humans ; Mice ; Polymerase Chain Reaction/methods ; Rats ; Receptors, Drug/agonists ; Receptors, Drug/antagonists & inhibitors ; Receptors, Drug/physiology
Chemical Substances	Cannabinoids ; Hallucinogens ; Receptors, Drug ; Acetylcholine (N9YNS0M02X)
Language	English
Publishing date	2001-02-06
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, P.H.S. ; Review
ZDB-ID	80128-8
ISSN	1468-3288 ; 0017-5749
ISSN (online)	1468-3288
ISSN	0017-5749
DOI	10.1136/gut.48.6.859
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 160: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Cannabinoid receptors and pain.

Pertwee, R G

Progress in neurobiology

2001 Volume 63, Issue 5, Page(s) 569–611

Abstract: Mammalian tissues contain at least two types of cannabinoid receptor, CB(1) and CB(2), both coupled to G proteins. CB(1) receptors are expressed mainly by neurones of the central and peripheral nervous system whereas CB(2) receptors occur centrally and ... ...

Abstract	Mammalian tissues contain at least two types of cannabinoid receptor, CB(1) and CB(2), both coupled to G proteins. CB(1) receptors are expressed mainly by neurones of the central and peripheral nervous system whereas CB(2) receptors occur centrally and peripherally in certain non-neuronal tissues, particularly in immune cells. The existence of endogenous ligands for cannabinoid receptors has also been demonstrated. The discovery of this 'endocannabinoid system' has prompted the development of a range of novel cannabinoid receptor agonists and antagonists, including several that show marked selectivity for CB(1) or CB(2) receptors. It has also been paralleled by a renewed interest in cannabinoid-induced antinociception. This review summarizes current knowledge about the ability of cannabinoids to produce antinociception in animal models of acute pain as well as about the ability of these drugs to suppress signs of tonic pain induced in animals by nerve damage or by the injection of an inflammatory agent. Particular attention is paid to the types of pain against which cannabinoids may be effective, the distribution pattern of cannabinoid receptors in central and peripheral pain pathways and the part that these receptors play in cannabinoid-induced antinociception. The possibility that antinociception can be mediated by cannabinoid receptors other than CB(1) and CB(2) receptors, for example CB(2)-like receptors, is also discussed as is the evidence firstly that one endogenous cannabinoid, anandamide, produces antinociception through mechanisms that differ from those of other types of cannabinoid, for example by acting on vanilloid receptors, and secondly that the endocannabinoid system has physiological and/or pathophysiological roles in the modulation of pain.
MeSH term(s)	Acute Disease ; Analgesics/therapeutic use ; Animals ; Brain/drug effects ; Brain/metabolism ; Cannabinoid Receptor Modulators ; Cannabinoids/therapeutic use ; Chronic Disease ; Disease Models, Animal ; Haplorhini ; Humans ; Ligands ; Mice ; Pain/drug therapy ; Pain/metabolism ; Pain/physiopathology ; Pain Measurement ; Rats ; Receptor, Cannabinoid, CB2 ; Receptors, Cannabinoid ; Receptors, Drug/agonists ; Receptors, Drug/antagonists & inhibitors ; Receptors, Drug/metabolism ; Spinal Cord/drug effects ; Spinal Cord/metabolism
Chemical Substances	Analgesics ; Cannabinoid Receptor Modulators ; Cannabinoids ; Cnr2 protein, rat ; Ligands ; Receptor, Cannabinoid, CB2 ; Receptors, Cannabinoid ; Receptors, Drug
Language	English
Publishing date	2001-04
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	185535-9
ISSN	1873-5118 ; 0301-0082
ISSN (online)	1873-5118
ISSN	0301-0082
DOI	10.1016/s0301-0082(00)00031-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Se 205: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: The pharmacology of cannabinoid receptors and their ligands: an overview

Pertwee, R.G

International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity. 2006 Apr., v. 30, suppl. 1

2006

Abstract	Mammalian tissues express at least two cannabinoid receptor types, CB1 and CB2, both G protein coupled. CB1 receptors are found predominantly at nerve terminals where they mediate inhibition of transmitter release. CB2 receptors occur mainly on immune cells, one of their roles being to modulate cytokine release. Endogenous agonists for cannabinoid receptors also exist, and are all eicosanoids. The first-discovered of these 'endocannabinoids' was arachidonoylethanolamide and there is convincing evidence that this ligand and some of its metabolites can activate vanilloid VRI (TRPV1) receptors. Certain cannabinoids also appear to have TRPV1-like and/or non-CB1, non-CB2, non-TRPV1 targets. Several CB1- and CB2-selective agonists and antagonists have been developed. Antagonists include the CB1-selective SR141716A, AM251, AM281 and LY320135, and the CB2-selective SR144528 and AM630. These all behave as inverse agonists, one indication that CB1 and CB2 receptors can exist in a constitutively active state. 'Neutral' cannabinoid receptor antagonists have also been developed. CB1 and/or CB2 receptor activation appears to ameliorate inflammatory and neuropathic pain and certain multiple sclerosis symptoms. This might be exploited clinically by using CB1, CB2 or CB1/CB2 agonists, or inhibitors of the membrane transport or catabolism of endocannabinoids that are released in increased amounts, at least in animal models of pain and multiple sclerosis. We have recently discovered the presence of an allosteric site on the CB1 receptor. Consequently, it may also prove possible to enhance 'autoprotective' effects of released endocannabinoids with CB1 allosteric enhancers or, indeed, to reduce proposed 'autoimpairing' effects of released endocannabinoids such as excessive food intake with CB1 allosteric antagonists.
Keywords	endogenous sources ; cannabinoids ; receptors ; pharmacology ; cytokines ; neural pathways ; biochemical pathways ; agonists ; antagonists ; human physiology ; immune system ; G-proteins ; eicosanoids
Language	English
Dates of publication	2006-04
Size	p. S13-S18.
Document type	Article
Note	Paper presented at the 6th International Symposium on The Endocannabinoid System and its Role in Energy Homeostasis and Abdominal Obesity Management held November 20, 2004 in Quebec City, Quebec, Canada.
Database	NAL-Catalogue (AGRICOLA)

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

To top

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Inter-library loan at ZB MED